World Investment Advisors Has $2.26 Million Stake in Royalty Pharma PLC $RPRX

World Investment Advisors raised its position in Royalty Pharma PLC (NASDAQ:RPRX) by 21.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 58,434 shares of the biopharmaceutical company’s stock after purchasing an additional 10,178 shares during the period. World Investment Advisors’ holdings in Royalty Pharma were worth $2,258,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Capital International Investors raised its stake in shares of Royalty Pharma by 24.4% in the 3rd quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock valued at $960,064,000 after purchasing an additional 5,332,074 shares during the period. State Street Corp increased its position in shares of Royalty Pharma by 0.8% in the third quarter. State Street Corp now owns 10,272,753 shares of the biopharmaceutical company’s stock valued at $362,423,000 after acquiring an additional 77,815 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Royalty Pharma by 3.7% in the third quarter. Victory Capital Management Inc. now owns 4,657,407 shares of the biopharmaceutical company’s stock valued at $164,313,000 after acquiring an additional 165,727 shares during the last quarter. Northern Trust Corp increased its position in shares of Royalty Pharma by 1.3% in the third quarter. Northern Trust Corp now owns 4,075,239 shares of the biopharmaceutical company’s stock valued at $143,774,000 after acquiring an additional 53,389 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Royalty Pharma by 10.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,282,174 shares of the biopharmaceutical company’s stock valued at $115,795,000 after acquiring an additional 305,694 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Trading Down 1.0%

Shares of RPRX stock opened at $52.85 on Friday. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock has a market cap of $30.43 billion, a P/E ratio of 35.95, a price-to-earnings-growth ratio of 1.47 and a beta of 0.40. The stock has a 50 day simple moving average of $48.31 and a 200 day simple moving average of $43.35. Royalty Pharma PLC has a 1 year low of $32.15 and a 1 year high of $53.47.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The business had revenue of $631.00 million during the quarter, compared to analysts’ expectations of $881.69 million. On average, research analysts predict that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.8%. Royalty Pharma’s dividend payout ratio is 63.95%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on RPRX shares. Citigroup lifted their target price on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley lifted their target price on Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, UBS Group boosted their price target on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $53.71.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 13,684 shares of the company’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.06, for a total value of $726,073.04. Following the sale, the executive vice president owned 31,881 shares in the company, valued at approximately $1,691,605.86. The trade was a 30.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the sale, the director owned 191,803 shares in the company, valued at $10,165,559. This trade represents a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 155,893 shares of company stock worth $7,512,360. Corporate insiders own 18.84% of the company’s stock.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.